Tasso Inc.

Tasso Inc., a Seattle-based for-profit corporation, manufactures and distributes whole liquid blood self-collection kits and associated diagnostic tracking services to federal agencies as a prime contractor operating entirely in full-and-open competition with no set-aside designations. The company competes 100% as a prime — it has no subcontractor relationships in its federal footprint — and operates a narrow, specialized capability focused on point-of-care biospecimen collection technology that enables remote, at-home diagnostic testing for veterans and military populations.

Tasso's federal customer concentration clusters heavily in Veterans Affairs. The top five customer agencies account for 92% of recent awards by count, with the VA Veterans Integrated Service Network (VISN) 1 and VISN 20 dominating through 16 total awards worth $10.6 million combined potential value. However, potential-value rankings surface a different profile: the Defense Threat Reduction Agency (DTRA) anchors the portfolio with a single $11.7 million award, and the Defense Advanced Research Projects Agency (DARPA) holds three awards worth $6.8 million combined. The Department of the Army Acquisition Support Center and the National Institutes of Health round out the active set. Most awards cluster under two parent Indefinite Delivery Contracts with VA VISN 1 and VISN 20, where Tasso holds the position of prime vendor for self-collection kit supply and fulfillment services. The VISN 1 IDC ceiling is $6.1 million with an ultimate completion date of February 28, 2027; the VISN 20 IDC ceiling is $905,000. Recent delivery orders under VISN 1 include a $671,160 order issued September 16, 2026 for kit distribution and tracking (completing March 10, 2027), a $500,040 order from March 2025 (completing March 10, 2026), and a $675,480 order from March 2024 (completed February 28, 2025). Place of performance is Jamaica Plain and Brockton, Massachusetts for VISN 1 work.

Tasso's activity has been episodic rather than growth-oriented — four awards in 2022, four in 2023, three in 2024, and one each in 2025 and 2026 — and only three awards (combined potential value $847,000) face ultimate completion within the next twenty-four months, limiting near-term recompete exposure. The company's broader federal portfolio spans research and development contracts from DARPA and the Defense Threat Reduction Agency valued in the millions, indicating work on biospecimen collection innovation and military medical readiness applications beyond the VA's logistics-focused orders. Combined potential value across all 25 prime awards is $34.1 million, with $24 million obligated as of the snapshot date (70% of ceiling). Service Contract Inventory data captures minimal activity — $602,000 in invoiced SCI-reportable services in FY2024 across 0.4 FTEs — reflecting Tasso's posture as a product and goods supplier rather than a labor-heavy services firm. The company operates independently, with no teaming partners or subcontract dependencies in the federal footprint.